Paper Details

  1. Home
  2. Paper Details

[Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs--dose-finding study in patients receiving cisplatin].

Author: AkasakaY, AriyoshiY, FurueH, IkedaM, NiitaniH, OhtaJ, OtaK, SuminagaM, TaguchiT, TsukagoshiS

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Ondansetron is an anti-nausea medication used to prevent nausea and vomiting caused by chemotherapy. This study found that a single intravenous dose of 4 mg ondansetron was effective in preventing nausea and vomiting caused by cisplatin chemotherapy and was well tolerated.
Paper Details　
Original Abstract of the Article :
We examined anti-emetic effects, safety and the optimal dose of Ondansetron Injection given in a single intravenous dose in patients receiving a single high dose of cisplatin in randomized controlled comparative study using telephone registration. Ondansetron was injected intravenously in a single d...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/1386975

データ提供：米国国立医学図書館（NLM）

Ondansetron: A Desert Oasis for Nausea and Vomiting

This research delves into the vast landscape of anti-emetics, a crucial field in cancer treatment. The study focuses on Ondansetron, a drug that acts like a calming oasis in the storm of nausea and vomiting caused by cisplatin, a potent cancer-fighting drug. Using a randomized controlled trial, researchers investigated the effectiveness and safety of Ondansetron in patients receiving high doses of cisplatin, exploring different dosages. They discovered that even the lowest dose of Ondansetron effectively suppressed nausea and vomiting, making it a reliable tool in the fight against these debilitating side effects.

A Low Dose, A Big Impact

The study found that a 4 mg dose of Ondansetron provided substantial relief from nausea and vomiting, comparable to higher doses. This is like discovering a small, yet powerful, spring in the desert that provides life-sustaining water. It demonstrates the potential for optimizing treatment regimens, minimizing side effects, and maximizing patient comfort.

Keeping the Camel Hydrated: A Safe Oasis

The study also underscored the safety profile of Ondansetron, reporting only mild side effects that resolved without treatment. This is like ensuring a camel has a safe and refreshing oasis to quench its thirst without fear of lurking dangers. The finding reinforces the importance of navigating the treacherous terrain of cancer treatment with safe and effective medications.

Dr.Camel's Conclusion

This study sheds light on the therapeutic potential of Ondansetron in mitigating the adverse effects of cisplatin therapy. It suggests that a low dose of Ondansetron can provide significant relief from nausea and vomiting while maintaining a favorable safety profile. This discovery is a beacon of hope for patients battling cancer, offering a comforting oasis amidst the challenges of treatment.
Date :
  1. Date Completed 1992-09-11
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

1386975

DOI: Digital Object Identifier

1386975

SNS
PICO Info
in preparation
Languages

Japanese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.